AbbVie Touts Positive Data For Multiple Myeloma Drug
AbbVie reports positive Phase 3 results for etentamig, showing higher response rates and improved survival in multiple myeloma patients.
AbbVie tested a new cancer medicine and got good results—more patients got better and lived longer. When a medicine company shares strong test results like this, it's a sign they might have a successful product to sell soon, which could help their business.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.